Movement Alert｜METIS TECHBIO-P Falls 6.26% in Regular Trading, Post-deal profit-taking persists after Lilly LNP collaboration

Market Focus10-22 09:48

On October 22, METIS TECHBIO-P fell 6.26% in regular trading, trading at HK$10.91, with turnover of HK$10.24 million.

The latest market-moving development points to continued post-announcement divergence after the company disclosed its strategic collaboration with Eli Lilly on next-generation tissue-specific LNP delivery technology.

Under the disclosed terms, METIS TECHBIO-P will receive an upfront payment in the low double-digit millions of US dollars and may earn up to about US$1.1 billion in development, regulatory and commercial milestone payments, plus single-digit tiered royalties on annual net sales. The collaboration uses its AI-driven AiLNP platform to discover and optimize novel lipid nanoparticle architectures for tissue-specific delivery, but the latest trading suggests investors are shifting focus toward realization timing and valuation digestion after the major deal announcement.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment